These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 31804465)

  • 1. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
    Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
    Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of p.G2019S Mutation in the
    Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
    J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
    Lee CY; Menozzi E; Chau KY; Schapira AHV
    J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.
    Burbulla LF; Zheng J; Song P; Jiang W; Johnson ME; Brundin P; Krainc D
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
    Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
    Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
    Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GBA1 K198E Variant Is Associated with Suppression of Glucocerebrosidase Activity, Autophagy Impairment, Oxidative Stress, Mitochondrial Damage, and Apoptosis in Skin Fibroblasts.
    Perez-Abshana LP; Mendivil-Perez M; Jimenez-Del-Rio M; Velez-Pardo C
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
    Volta M
    Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
    Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Yang SY; Gegg M; Chau D; Schapira A
    Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease in a dish - Using stem cells as a molecular tool.
    Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
    Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
    Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
    Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotenone Blocks the Glucocerebrosidase Enzyme and Induces the Accumulation of Lysosomes and Autophagolysosomes Independently of LRRK2 Kinase in HEK-293 Cells.
    Perez-Abshana LP; Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
    Usenko TS; Senkevich KA; Basharova KS; Bezrukova AI; Baydakova GV; Tyurin AA; Beletskaya MV; Kulabukhova DG; Grunina MN; Emelyanov AK; Miliukhina IV; Timofeeva AA; Zakharova EY; Pchelina SN
    Gene; 2023 Oct; 882():147639. PubMed ID: 37473971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.